Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Ann A. Lawyer"'
Autor:
Nikhil G. Thaker, Alexis B. Guzman, Lilie L. Lin, Ann A. Lawyer, Jihong Wang, Christine Starks, Jingfei Ma, James R. Incalcaterra, Aradhana M. Venkatesan, Mandy G. Cunningham, Ann H. Klopp, Matthew S. Ning, R. Jason Stafford, Sastry Vedam, Anuja Jhingran, Li Wang, Nicholas D. Olivieri, Melissa M. Joyner, Teresa L. Bruno, Patricia J. Eifel
Publikováno v:
Brachytherapy. 19:305-315
Purpose The purpose of this study was to investigate the utility of a novel MRI-positive line marker, composed of C4:S (cobalt chloride–based contrast agent) encapsulated in high-density polyethylene tubing, in permitting dosimetry and treatment pl
Autor:
Ann H. Klopp, Ann A. Lawyer, Todd A. Pezzi, Shane Mesko, David Boyce-Fappiano, Anuja Jhingran, Nikhil G. Thaker, Nicholas D. Olivieri, Alexis B. Guzman, Matthew S. Ning, Lilie L. Lin, Steven J. Frank, Simona F. Shaitelman, Patricia J. Eifel, Sastry Vedam, James R. Incalcaterra
Publikováno v:
Brachytherapy. 18:445-452
Purpose The purpose of this study was to quantify the cost of resources required to deliver adjuvant radiation therapy (RT) for high- to intermediate-risk endometrial cancer using time-driven activity-based costing (TDABC). Methods and Materials Comp
Autor:
K. Ranh Voong, William H. Morrison, Beth M. Beadle, Adam S. Garden, Dan S. Gombos, Firas Mourtada, Ann A. Lawyer, Laura A. Rechner, Vinita Takiar
Publikováno v:
Practical Radiation Oncology. 5:e169-e176
Both iodine-125 ((125)I) Collaborative Ocular Melanoma Study and ruthenium-106 ((106)Ru) eye plaques can achieve excellent tumor control in patients diagnosed with uveal melanoma. We analyzed our single institutional experience in the management of o
Autor:
Paula A. Berner, Sanjay Gupta, Andrew J. Bishop, Randa Tao, Christopher H. Crane, Geoffrey S. Ibbott, Mandy G. Cunningham, Ann A. Lawyer, Samantha G. Korpela
Publikováno v:
Annals of Surgical Oncology. 22:596-602
Local tumor control (LC), overall survival (OS), symptom palliation, and late toxicity for patients with locally recurrent anorectal cancer treated with a computed tomography (CT)-guided interstitial brachytherapy implant were examined. The medical r
Autor:
Michael Gillin, Firas Mourtada, Kent A Gifford, John L. Horton, Michael J. Price, Patricia J. Eifel, Ann A. Lawyer
Publikováno v:
Medical Physics. 36:4147-4155
Purpose: Current, clinically applicable intracavitary brachytherapy applicators that utilize shielded ovoids contain a pair of tungsten-alloy shields which serve to reduce dose delivered to the rectum and bladder during source afterloading. After app
Autor:
Paula A. Berner, Kent A Gifford, Patricia J. Eifel, John L. Horton, Michael J. Price, Firas Mourtada, Ann A. Lawyer
Publikováno v:
Medical Dosimetry. 32:181-187
The purpose of this study was to compare the dose distribution of Iridium-192 ({sup 192}Ir) pulsed-dose-rate (PDR) brachytherapy to that of Cesium-137 ({sup 137}Cs) low-dose-rate (LDR) brachytherapy around mini-ovoids and an intrauterine tandem. Ten
Publikováno v:
Radiotherapy and Oncology. 77:210-215
Background and purpose Dose rate distributions around Fletcher Suit Delclos (FSD) tandem applicators used for intracavitary brachytherapy are usually calculated by assuming each source is a point source and summing the contributions from each of the
Autor:
Kent A Gifford, Patricia J. Eifel, Firas Mourtada, Michael J. Price, Anuja Jhingran, Ann A. Lawyer, Paula A. Berner, John L. Horton
Publikováno v:
Physics in Medicine and Biology. 50:5075-5087
We used radiochromic film dosimetry to validate a Monte Carlo (MC) model of a 192Ir pulsed-dose-rate (PDR) source inside a Fletcher-Williamson ovoid. MD-55-2 radiochromic film was placed in a high-impact polystyrene phantom in a plane parallel to and
Autor:
Edward F. Jackson, John L. Horton, Geoffrey S. Ibbott, Firas Mourtada, M Heard, Kent A Gifford, Ann A. Lawyer, Theodore R. Steger
Publikováno v:
Medical Physics. 32:2288-2294
The Fletcher Suit Delclos (FSD) ovoids employed in intracavitary brachytherapy (ICB) for cervical cancer contain shields to reduce dose to the bladder and rectum. Many treatment planning systems (TPS) do not include the shields and other ovoid struct
Publikováno v:
Medical Dosimetry. 24:273-277
Treatment of prostate cancer utilizing iodine 125 (125I) interstitial seed implants has become an accepted and widely used modality. Numerous variations in 125I seed implant loading distribution techniques have developed as a result of the preference